{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:47:39Z","timestamp":1793040459031,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/J003018\/1"],"award-info":[{"award-number":["BB\/J003018\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/R000344\/1"],"award-info":[{"award-number":["BB\/R000344\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106244\/Z\/14\/Z"],"award-info":[{"award-number":["106244\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","award":["75F40120C00085"],"award-info":[{"award-number":["75F40120C00085"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejmech.2025.117603","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:52:58Z","timestamp":1744116778000},"page":"117603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies"],"prefix":"10.1016","volume":"291","author":[{"given":"D\u00f3ra","family":"Laczi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia Sch\u00f6nbauer","family":"Huam\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylah","family":"Andrews-Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Laidlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eidarus","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Dumjahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Lukacik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles W.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0290-6565","authenticated-orcid":false,"given":"Christopher J.","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Brewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117603_bib1","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117603_bib2","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117603_bib3","first-page":"9","article-title":"Discovery of GST-HG171, a potent and selective oral 3CL protease inhibitor for the treatment of COVID-19","volume":"6","author":"Zhang","year":"2023","journal-title":"SM J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117603_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41564-024-01618-9","article-title":"Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir","volume":"9","author":"Chen","year":"2024","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2025.117603_bib5","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02013-21","article-title":"Structural basis of the main proteases of coronavirus bound to drug candidate PF-07321332","volume":"96","author":"Li","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.117603_bib7","doi-asserted-by":"crossref","first-page":"34196","DOI":"10.1021\/acsomega.4c03023","article-title":"Progress in research on inhibitors targeting SARS-CoV-2 main protease (Mpro)","volume":"9","author":"Yang","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.117603_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.apsb.2023.08.004","article-title":"Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors","volume":"14","author":"Song","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117603_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117603_bib10","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","article-title":"Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities","volume":"65","author":"Cannalire","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib11","doi-asserted-by":"crossref","first-page":"16922","DOI":"10.1021\/acs.jmedchem.1c00409","article-title":"Perspectives on SARS-CoV-2 main protease inhibitors","volume":"64","author":"Gao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib12","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1039\/D1MD00066G","article-title":"A review of the latest research on Mpro targeting SARS-COV inhibitors","volume":"12","author":"Yang","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1039\/D3MD00493G","article-title":"On the origins of SARS-CoV-2 main protease inhibitors","volume":"15","author":"Janin","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate Covid-19","volume":"390","author":"Cao","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117603_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117603_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102582","article-title":"Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"71","author":"Lu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejmech.2025.117603_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102359","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejmech.2025.117603_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejmech.2025.117603_bib23","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","article-title":"A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19","volume":"67","author":"Allerton","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib24","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1021\/acs.jmedchem.2c00404","article-title":"Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib19","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/s41467-022-29915-z","article-title":"Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease","volume":"13","author":"Kneller","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117603_bib20","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.bmcl.2010.01.037","article-title":"Towards the second generation of boceprevir: dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors","volume":"20","author":"Nair","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117603_bib21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1021\/jm00401a014","article-title":"Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines","volume":"31","author":"Krapcho","year":"1988","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib22","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1021\/jm00127a033","article-title":"Angiotensin converting enzyme inhibitors: spirapril and related compounds","volume":"32","author":"Smith","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","article-title":"SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging","volume":"17","author":"Rut","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117603_bib26","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1038\/s41467-022-32854-4","article-title":"X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117603_bib27","article-title":"Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2","volume":"119","author":"Zhao","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.117603_bib28","doi-asserted-by":"crossref","first-page":"13686","DOI":"10.1039\/D1SC03628A","article-title":"Discovery of SARS-CoV-2 Mpro peptide inhibitors from modelling substrate and ligand binding","volume":"12","author":"Chan","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2025.117603_bib29","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/cid\/ciae529","article-title":"Virologic response and safety of ibuzatrelvir, a novel SARS-CoV-2 antiviral, in adults with COVID-19","volume":"80","author":"Mortezavi","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117603_bib30","doi-asserted-by":"crossref","first-page":"11656","DOI":"10.1021\/acs.jmedchem.4c01342","article-title":"Fixing the achilles heel of Pfizer's paxlovid for COVID-19 treatment","volume":"67","author":"Brewitz","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib31","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1021\/acs.oprd.4c00202","article-title":"Sustainable manufacturing of trans-4-trifluoromethyl-L-proline via stereochemical editing: a combined in silico and experimental approach","volume":"28","author":"Algera","year":"2024","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2025.117603_bib32","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1021\/ja017440q","article-title":"Influence of silaproline on peptide conformation and bioactivity","volume":"124","author":"Cavelier","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117603_bib33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/jm3010114","article-title":"Organosilicon molecules with medicinal applications","volume":"56","author":"Franz","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib34","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/jm1013693","article-title":"Synopsis of some recent tactical application of bioisosteres in drug design","volume":"54","author":"Meanwell","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib35","doi-asserted-by":"crossref","first-page":"8479","DOI":"10.1021\/ja060036c","article-title":"Replacement of a proline with silaproline causes a 20-fold increase in the cellular uptake of a pro-rich peptide","volume":"128","author":"Pujals","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117603_bib36","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1039\/D4MD00169A","article-title":"The role of silicon in drug discovery: a review","volume":"15","author":"Panayides","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib37","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.bmcl.2016.01.050","article-title":"Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development","volume":"26","author":"Nair","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117603_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127039","article-title":"Novel cilengitide-based cyclic RGD peptides as \u03b1v\u03b23 integrin inhibitors","volume":"30","author":"Meena","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117603_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.dib.2020.105884","article-title":"Data set describing the in vitro biological activity of JMV2009, a novel silylated neurotensin(8\u201313) analog","volume":"31","author":"Besserer-Offroy","year":"2020","journal-title":"Data Brief"},{"key":"10.1016\/j.ejmech.2025.117603_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/psc.1201","article-title":"Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme","volume":"16","author":"Dalkas","year":"2010","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.ejmech.2025.117603_bib41","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.bmcl.2018.03.049","article-title":"MK-8325: a silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV","volume":"28","author":"Nair","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117603_bib42","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/(SICI)1099-0690(200003)2000:5<807::AID-EJOC807>3.0.CO;2-E","article-title":"Synthesis of silaproline, a new proline surrogate","author":"Vivet","year":"2000","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1515\/znb-2000-0201","article-title":"Sila-substitution of the \u03b1-amino acid proline: synthesis of rac- and (R)-4,4-dimethyl-4-sila-proline ethyl ester","volume":"55b","author":"Handmann","year":"2000","journal-title":"Z. Naturforsch."},{"key":"10.1016\/j.ejmech.2025.117603_bib44","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1055\/a-1755-3832","article-title":"Synthetic approaches for the construction of five- and six-membered silaazacycles","volume":"54","author":"Wang","year":"2022","journal-title":"Synthesis"},{"key":"10.1016\/j.ejmech.2025.117603_bib45","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1021\/acs.orglett.6b00548","article-title":"Asymmetric synthesis of N-Boc-(R)-silaproline via Rh-catalyzed intramolecular hydrosilylation of dehydroalanine and continuous flow N-alkylation","volume":"18","author":"Chung","year":"2016","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2025.117603_bib46","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1021\/ja00063a082","article-title":"1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive","volume":"115","author":"Carpino","year":"1993","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117603_bib48","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/cber.19580910223","article-title":"Spezifische Protonenacceptoren als Hilfsbasen bei Alkylierungs- und Dehydrohalogenierungsreaktionen","volume":"91","author":"H\u00fcnig","year":"1958","journal-title":"Chem. Ber."},{"key":"10.1016\/j.ejmech.2025.117603_bib47","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1021\/acs.jmedchem.3c02248","article-title":"Invention of MK-7845, a SARS-CoV-2 3CL protease inhibitor employing a novel difluorinated glutamine mimic","volume":"67","author":"Shurtleff","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib49","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1039\/D0CC06870E","article-title":"Mass spectrometry reveals potential of \u03b2-lactams as SARS-CoV-2 Mpro inhibitors","volume":"57","author":"Malla","year":"2021","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.117603_bib50","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1021\/acs.jmedchem.1c02214","article-title":"Penicillin derivatives inhibit the SARS-CoV-2 main protease by reaction with its nucleophilic cysteine","volume":"65","author":"Malla","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib51","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1021\/acs.jmedchem.2c01627","article-title":"Alkyne derivatives of SARS-CoV-2 main protease inhibitors including nirmatrelvir inhibit by reacting covalently with the nucleophilic cysteine","volume":"66","author":"Brewitz","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/bulcsj\/uoae018","article-title":"Cyclic \u03b22,3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease","volume":"97","author":"Miura","year":"2024","journal-title":"Bull. Chem. Soc. Jpn."},{"key":"10.1016\/j.ejmech.2025.117603_bib53","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41557-023-01205-1","article-title":"In vitro selection of macrocyclic peptide inhibitors containing cyclic \u03b32,4-amino acids targeting the SARS-CoV-2 main protease","volume":"15","author":"Miura","year":"2023","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200016","article-title":"Mass spectrometric assays reveal discrepancies in inhibition profiles for the SARS-CoV-2 papain-like protease","volume":"17","author":"Brewitz","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117603_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117498","article-title":"Mass spectrometric assays monitoring the deubiquitinase activity of the SARS-CoV-2 papain-like protease inform on the basis of substrate selectivity and have utility for substrate identification","volume":"95","author":"Brewitz","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1039\/D3CB00128H","article-title":"Studies on the selectivity of the SARS-CoV-2 papain-like protease reveal the importance of the P2\u2032 proline of the viral polyprotein","volume":"5","author":"Chan","year":"2024","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117603_bib57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ejmech.2025.117603_bib58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1087057116671509","article-title":"A perspective on the kinetics of covalent and irreversible inhibition","volume":"22","author":"Strelow","year":"2017","journal-title":"SLAS Discov"},{"key":"10.1016\/j.ejmech.2025.117603_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.419","article-title":"A comprehensive guide for assessing covalent inhibition in enzymatic assays illustrated with kinetic simulations","volume":"2","author":"Mons","year":"2022","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.ejmech.2025.117603_bib60","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1039\/D1SC06596C","article-title":"Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide","volume":"13","author":"Yamane","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2025.117603_bib61","doi-asserted-by":"crossref","first-page":"14986","DOI":"10.1021\/acs.jmedchem.4c00535","article-title":"Nonpeptidic irreversible inhibitors of SARS-CoV-2 main protease with potent antiviral activity","volume":"67","author":"Oneto","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib62","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.chembiol.2021.05.018","article-title":"An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor","volume":"28","author":"Zaidman","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117603_bib63","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3390\/ph16040547","article-title":"Technologies for direct detection of covalent protein\u2013drug adducts","volume":"16","author":"Mons","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117603_bib64","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/1087057115621288","article-title":"High-throughput mass spectrometric analysis of covalent protein-inhibitor adducts for the discovery of irreversible inhibitors: a complete workflow","volume":"21","author":"Campuzano","year":"2016","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ejmech.2025.117603_bib65","doi-asserted-by":"crossref","first-page":"12859","DOI":"10.1039\/D3CC02932H","article-title":"\u03b1\u03b2,\u03b1\u2032\u03b2\u2032-Diepoxyketones are mechanism-based inhibitors of nucleophilic cysteine enzymes","volume":"59","author":"de Munnik","year":"2023","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.117603_bib66","article-title":"Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19","volume":"11","author":"Redhead","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117603_bib67","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1039\/D4SC01027B","article-title":"Thiophene-fused \u03b3-lactams inhibit the SARS-CoV-2 main protease via reversible covalent acylation","volume":"15","author":"Gayatri","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2025.117603_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100582","article-title":"Structure-activity studies reveal scope for optimisation of ebselen-type inhibition of SARS-CoV-2 main protease","volume":"17","author":"Thun-Hohenstein","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117603_bib69","first-page":"2535","article-title":"Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117603_bib70","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1021\/jo00147a022","article-title":"Conformational preference of the trimethylsilyl group","volume":"47","author":"Kitching","year":"1982","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib71","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jacs.8b03187","article-title":"Synthesis, reactivity, functionalization, and ADMET properties of silicon-containing nitrogen heterocycles","volume":"140","author":"Barraza","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117603_bib72","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1021\/acs.jmedchem.0c00082","article-title":"Discovery of a silicon-containing pan-genotype hepatitis C virus NS5A inhibitor","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib73","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejmech.2018.02.025","article-title":"Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity","volume":"148","author":"Liu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib74","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejmech.2017.04.038","article-title":"Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses","volume":"135","author":"Hu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib75","doi-asserted-by":"crossref","first-page":"13844","DOI":"10.1021\/ja2050666","article-title":"Exploring organosilane amines as potent inhibitors and structural probes of influenza A virus M2 proton channel","volume":"133","author":"Wang","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117603_bib76","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1074-5521(01)00079-5","article-title":"Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease","volume":"8","author":"Chen","year":"2001","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117603_bib77","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/(SICI)1521-3773(19980403)37:6<812::AID-ANIE812>3.0.CO;2-I","article-title":"Silanediols: a new class of potent protease inhibitors","volume":"37","author":"Sieburth","year":"1998","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.117603_bib78","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1021\/ja026158w","article-title":"Silicon-based metalloprotease inhibitors: synthesis and evaluation of silanol and silanediol peptide analogues as inhibitors of angiotensin-converting enzyme","volume":"124","author":"Mutahi","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117603_bib79","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1016\/S0960-894X(02)00804-1","article-title":"Silanediol-based inhibitor of thermolysin","volume":"12","author":"Kim","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117603_bib80","doi-asserted-by":"crossref","first-page":"16524","DOI":"10.1021\/bi051346v","article-title":"Structural analysis of silanediols as transition-state-analogue inhibitors of the benchmark metalloprotease thermolysin","volume":"44","author":"Juers","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.117603_bib81","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1021\/jm301000k","article-title":"Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase","volume":"55","author":"Madsen","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib82","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1021\/acs.joc.8b00116","article-title":"Asymmetric synthesis of silanediol inhibitors for the serine protease coagulation Cascade enzyme FXIa","volume":"83","author":"Duong","year":"2018","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib83","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1021\/ol301933n","article-title":"Serine protease inhibition by a silanediol peptidomimetic","volume":"14","author":"Singh","year":"2012","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2025.117603_bib84","unstructured":"L.D. Arnold, A. Jennings, W. Keung, Inhibitors of cysteine proteases and methods of use thereof WO2021\/252644A1."},{"key":"10.1016\/j.ejmech.2025.117603_bib85","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1021\/acs.jmedchem.7b00718","article-title":"Quest for novel chemical entities through incorporation of silicon in drug scaffolds","volume":"61","author":"Ramesh","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib86","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.clinre.2011.02.009","article-title":"Efficacy of a simethicone, activated charcoal and magnesium oxide combination (carbosymag\u00ae) in functional dyspepsia: results of a general practice-based randomized trial","volume":"35","author":"Coffin","year":"2011","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.ejmech.2025.117603_bib87","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000286002","article-title":"Review of the therapeutic use of simethicone in gastroenterology","volume":"19","author":"Meier","year":"2007","journal-title":"Schweiz. Zschr. Ganzheitsmedizin"},{"key":"10.1016\/j.ejmech.2025.117603_bib88","series-title":"Synthesis and Chemistry of Agrochemicals","first-page":"288","article-title":"Biologically active organosilicon compounds","author":"Moberg","year":"1987"},{"key":"10.1016\/j.ejmech.2025.117603_bib89","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","article-title":"Triazole antifungal agents in invasive fungal infections","volume":"71","author":"Lass-Fl\u00f6rl","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117603_bib90","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117603_bib91","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1021\/acscatal.4c06020","article-title":"Mechanistic insights into nitrile and alkyne covalent inhibitors of the SARS-CoV-2 main protease","volume":"15","author":"Nandi","year":"2025","journal-title":"ACS Catal."},{"key":"10.1016\/j.ejmech.2025.117603_bib92","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/ja309802n","article-title":"On terminal alkynes that can react with active-site cysteine nucleophiles in proteases","volume":"135","author":"Ekkebus","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117603_bib93","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.bmc.2013.02.039","article-title":"Covalent inhibition of SUMO and ubiquitin-specific cysteine proteases by an in situ thiol\u2013alkyne addition","volume":"21","author":"Sommer","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib94","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117603_bib95","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.117603_bib96","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1021\/jacs.8b11027","article-title":"The alkyne moiety as a latent electrophile in irreversible covalent small molecule inhibitors of cathepsin K","volume":"141","author":"Mons","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117603_bib97","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1021\/acs.jmedchem.3c01804","article-title":"Discovery of orally available and brain penetrant AEP inhibitors","volume":"66","author":"Krummenacher","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114046","article-title":"Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors","volume":"229","author":"Stille","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib99","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41467-023-37254-w","article-title":"Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2","volume":"14","author":"Sanders","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117603_bib100","doi-asserted-by":"crossref","first-page":"20697","DOI":"10.1021\/jacs.1c08060","article-title":"Discovery of di- and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity","volume":"143","author":"Ma","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117603_bib101","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1038\/s41467-020-18709-w","article-title":"Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease","volume":"11","author":"Douangamath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117603_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129531","article-title":"Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition","volume":"1864","author":"Liclican","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.ejmech.2025.117603_bib103","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.117603_bib104","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1021\/acs.jmedchem.6b01395","article-title":"4-Hydroxyphenylpyruvate dioxygenase and its inhibition in plants and animals: small molecules as herbicides and agents for the treatment of human inherited diseases","volume":"60","author":"Santucci","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib105","doi-asserted-by":"crossref","first-page":"8523","DOI":"10.1021\/acs.jafc.7b03851","article-title":"4-Hydroxyphenylpyruvate dioxygenase inhibitors: from chemical biology to agrochemicals","volume":"65","author":"Ndikuryayo","year":"2017","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib106","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/acs.jafc.0c03844","article-title":"Structure-guided discovery of silicon-containing subnanomolar inhibitor of hydroxyphenylpyruvate dioxygenase as a potential herbicide","volume":"69","author":"Qu","year":"2021","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib107","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41557-023-01249-3","article-title":"A locally activatable sensor for robust quantification of organellar glutathione","volume":"15","author":"Emmert","year":"2023","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib108","doi-asserted-by":"crossref","first-page":"32274","DOI":"10.1074\/jbc.M103285200","article-title":"The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin","volume":"276","author":"Fotinou","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib109","doi-asserted-by":"crossref","first-page":"32774","DOI":"10.1074\/jbc.M601714200","article-title":"Siglec-7 undergoes a major conformational change when complexed with the \u03b1(2,8)-disialylganglioside GT1b","volume":"281","author":"Attrill","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib110","doi-asserted-by":"crossref","first-page":"21505","DOI":"10.1021\/acs.jmedchem.4c02404","article-title":"First sila-vitamin D analogues: design, synthesis, structural analysis and biological activity","volume":"67","author":"Loureiro","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib111","doi-asserted-by":"crossref","first-page":"11058","DOI":"10.1039\/D0CC05026A","article-title":"Cu(II)-Catalysed \u03b2-silylation of dehydroalanine residues in peptides and proteins","volume":"56","author":"de Vries","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.117603_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105365","article-title":"Potent and biostable inhibitors of the main protease of SARS-CoV-2","volume":"25","author":"Tsuji","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2025.117603_bib113","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41467-023-36729-0","article-title":"Identification of SARS-CoV-2 Mpro inhibitors containing P1\u2019 4-fluorobenzothiazole moiety highly active against SARS-CoV-2","volume":"14","author":"Higashi-Kuwata","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117603_bib114","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117603_bib115","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117603_bib116","doi-asserted-by":"crossref","first-page":"18206","DOI":"10.1021\/acsomega.2c01121","article-title":"Fluorine in medicinal chemistry: in perspective to COVID-19","volume":"7","author":"Zhang","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.117603_bib117","doi-asserted-by":"crossref","first-page":"10633","DOI":"10.1021\/acsomega.0c00830","article-title":"Contribution of organofluorine compounds to pharmaceuticals","volume":"5","author":"Inoue","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.117603_bib118","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib119","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/jm0493156","article-title":"(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Kim","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib120","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.1021\/acs.joc.1c02956","article-title":"Fluorine-containing prolines: synthetic strategies, applications, and opportunities","volume":"87","author":"Mykhailiuk","year":"2022","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.117603_bib121","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117603_bib122","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5694\/mja2.50569","article-title":"Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia","volume":"212","author":"Caly","year":"2020","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ejmech.2025.117603_bib123","first-page":"1260","article-title":"Decision making in xia2","volume":"D69","author":"Winter","year":"2013","journal-title":"Acta Crystallogr."},{"key":"10.1016\/j.ejmech.2025.117603_bib124","first-page":"1204","article-title":"How good are my data and what is the resolution?","volume":"D69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr."},{"key":"10.1016\/j.ejmech.2025.117603_bib125","first-page":"22","article-title":"Molecular replacement with MOLREP","volume":"D66","author":"Vagin","year":"2010","journal-title":"Acta Crystallogr."},{"key":"10.1016\/j.ejmech.2025.117603_bib126","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500368X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500368X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:40:24Z","timestamp":1778042424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342500368X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":126,"alternative-id":["S022352342500368X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117603","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117603"}}